Toggle Nav
  • Menu
  • Setting

Pergolide mesylate

Catalog No.
Dopaminergic agonist
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
In stock
Evaluation Sample
In stock
In stock
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


Pergolide mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
Cas No.66104-23-2
Solubilityinsoluble in EtOH; insoluble in H2O; ≥6.84 mg/mL in DMSO
Chemical Name(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid
SDFDownload SDF
Shipping ConditionShip with blue ice, or upon other requests.
General tipsFor obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon.


Cell experiment [1]:

Cell lines

SH-SY5Y neuroblastoma cell

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

10 nM to 50 μM


Pergolide dose-dependently protected neuroblastoma cells from H2O2-induced neurotoxicity with IC50 values of pergolide of about 40 and 60 nM. Incubation of the cells with 1 μM pergolide for 26 h did not affect cell viability. Preincubation of the cells with 100 nM pergolide for 2 h before the cytotoxic agent did not affect the neurotoxic effect of either doxorubicin or cis-platinum.

Animal experiment [2,3]:

Animal models

Female rats

Dosage form

Intraperitoneal injection, 0.5 mg/kg/day, 7 days


In spayed female rats, pergolide mesylate significantly suppressed food intake and body weight. Inhibition of food intake by a constant dose of pergolide progressively diminished with repeated administrations. Pergolide suppressed body weight with no indications of tolerance. In rats treated with pergolide mesylate (7 days 0.5 mg/kg/day, i.p.), the average amount of 2,3-DHBA associated with 6-OHDA striatal infusion was significantly smaller than that in controls. Pergolide treatment led to an increased ability of striatal tissue to quench hydroxyl radical formation in vivo.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Uberti D, Piccioni L, Colzi A, et al. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H 2 O 2[J]. European journal of pharmacology, 2002, 434(1): 17-20.

[2]. Greene S B, Mathews D, Hollingsworth E M, et al. Behavioral effects of pergolide mesylate on food intake and body weight[J]. Pharmacology Biochemistry and Behavior, 1985, 23(2): 161-167.

[3]. Opacka-Juffry J, Wilson A W, Blunt S B. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum[J]. Brain research, 1998, 810(1): 27-33.

Quality Control

Chemical structure

Pergolide mesylate